

1/63




Figure 1

2/63




Figure 2A

3/63




Figure 2B

4/63




Figure 3

5/63




Figure 4




Figure 5

7/63




Figure 6

8/63




Figure 7

9/63




Figure 8A

10/63




Figure 8B

11/63







Figure 8C

12/63



Figure 8D

13/63

14:0 LPG**18:0 LPG****18:1 LPG****Figure 9**

14/63




Figure 10

15/63




Figure 11

16/63




Figure 12

17/63




Figure 13

18/63




Figure 14

19/63




Figure 15

20/63




Figure 16

21/63

Concentration-dependent inhibition




Figure 17

22/63

Curve-shift




Figure 18

23/63




Figure 19

24/63




Figure 20

25/63




Figure 21

26/63




Figure 22

27/63

Control (serum-free)




Figure 23

28/63

18:0 LPG 10 μ M




Figure 24

29/63

18:0 LPG 30 μ M




Figure 25

30/63

14:0 LPA 10 μ M




Figure 26

31/63

14:0 LPA 10 μ M + 18:0 LPE 10 μ M




Figure 27

32/63

14:0 LPA 10 μ M + 18:0 LPG 30 μ M




Figure 28

33/63

Control




Figure 29

34/63

10 μ M 18:0 LPG




Figure 30

35/63

30 μ M 18:0 LPG




Figure 31

36/63

Control




Figure 32

37/63

10 μ M 18:0 LPG




Figure 33

38/63

30 μ M 18:0 LPG




Figure 34

39/63




Figure 35

40/63




Figure 36

41/63

Control (Serum-free)




Figure 37

42/63

14:0 LPG (30 μ M) : LPA1 antagonist




Figure 38

43/63

18:0 LPG (30 μ M) : LPA1/2 antagonist




Figure 39

44/63

18:1 LPG (30 μ M) : LPA1/2/3 antagonist




Figure 40

45/63

Control (18:1 LPA 10 μ M)




Figure 41

46/63

18:1 LPA 10 μ M + 14:0 LPG (30 μ M)




Figure 42

47/63

18:1 LPA $10\mu\text{M}$ + 18:0 LPG ($30\mu\text{M}$)




Figure 43

48/63

18:1 LPA $10\mu\text{M}$ + 18:1 LPG ($30\mu\text{M}$)





Figure 44

49/63

**Figure 45**

50/63




Figure 46

51/63




Figure 47

52/63

	Inhibition (%)	
	Without LPA	With LPA
14:0 LPG (30 μ M)	8%	26% ↑
18:0 LPG (30 μ M)	41%	37%
18:1 LPG (30 μ M)	29%	39% ↑

Figure 48

53/63




Figure 49

54/63

	Inhibition (%)	
	Without LPA	With LPA
14:0 LPG (30 μ M)	4%	16% ↑
18:0 LPG (30 μ M)	46%	49%
18:1 LPG (30 μ M)	13%	32% ↑

Figure 50

55/63




Figure 51

56/63




Figure 52

57/63




Figure 53

58/63





Figure 54

59/63

**Figure 55**

60/63







Figure 56

61/63

**Figure 57**

**Figure 58**

**Figure 59**